Guardant Health (NASDAQ:GH) is a $6 billion+ market capitalization precision oncology testing company that is developing some exciting new technology in the cancer space. The company announced the closing of its initial public offering on October 9 of last year, raising just over $270 million in cash to fund future growth. With the company reporting earnings later this week, it's worth a closer look.
Company Fundamentals
The company's stated mission is to "conquer cancer with data". In the exciting world of oncology, this is a lofty and admirable mission. The company is developing